Association of lopinavir concentrations with plasma lipid or glucose concentrations in HIV-infected South Africans: A cross sectional study

AIDS Research and Therapy

Volumn 9, Issue , 2012, Pages

  Sinxadi, Phumla Z ^a   McIlleron, Helen M ^a   Dave, Joel A ^a   Smith, Peter J ^a   Levitt, Naomi S ^a   Maartens, Gary ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Antiretroviral therapy; Hypercholesterolaemia; Hypertriglyceridaemia; Impaired glucose metabolism; Lopinavir; Pharmacokinetics

Indexed keywords

CHOLESTEROL; GLUCOSE; LIPID; LOPINAVIR; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET RESTRICTION; DYSGLYCEMIA; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGRESSION ANALYSIS; SOUTH AFRICA; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST HIP RATIO;

EID: 84867812897     PISSN: None     EISSN: 17426405     Source Type: Journal    
DOI: 10.1186/1742-6405-9-32     Document Type: Article

References (25)

1. World Health Organization Rapid advice antiretroviral therapy for HIV infection in adults and adolescents 2009, World Health Organization, downloaded from http://www.who.int/hiv/pub/arv/rapid_advice_art.pdf on 03 August 2011, World Health Organization.
2. De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Cazanave C, El-Sadr C, Monforte W, Fontas A, Law E, Friis-Møller MG, Phillips N. Incidence and risk factors for new onset diabetes in HIV-infected patients. The data collection on adverse events of anti-HIV drugs (D: A: D) study. Diabetes Care 2008, 31:1224-1229. 10.2337/dc07-2013, 2746200, 18268071.
3. Montes ML, Pulido F, Barros C, Condes E, Rubio R, Cepeda C, Dronda F, Antela A, Sanz J, Navas E, Miralles P, Berenguer J, Pérez S, Zapata A, González-García JJ, Peña JM, Vázquez JJ, Arribas JR. Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors. JAC 2005, 55:800-804.
4. Anastos K, Lu D, Shi Q, Tien PC, Kaplan RC, Hessol NA, Cole S, Vigen C, Cohen M, Young M, Justman J. Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. J Acquir Immune Defic Syndr 2007, 45:34-42. 10.1097/QAI.0b013e318042d5fe, 17460470.
5. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction and natural course of HIV-1 protease-inhibitor associated lipodystrophy hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353:2093-2099. 10.1016/S0140-6736(98)08468-2, 10382692.
6. Galindo MJ, Verdejo J, Gonzalez-Mun M, Ferrer A, Polo R. Metabolic changes in protease inhibitor-naïve patients with lopinavir/ritonavir. J Acquir Immune Defic Syndr 2008, 48:628-629. 10.1097/QAI.0b013e31816d9cf8, 18665024.
7. Dube' MP, Shen C, Greenwald M, Mather KJ. No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: A placebo-controlled trial. Clinical Infectious Disease 2008, 47:567-574.
8. Pao VY, Lee GA, Taylor S, Aweeka FT, Schwarz JM, Mulligan K, Schambelan M, Grunfeld C. The protease inhibitor combination lopinavir/ritonavir does not decrease insulin secretion in healthy, HIV-seronegative volunteers. AIDS 2010, 24:265-270. 10.1097/QAD.0b013e328333af1c, 19890203.
9. Lee GA, Lo JC, Aweeka F, Schwarz JM, Mulligan K, Schambelan M, Grunfeld C. Single-dose lopinavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers. Clin Infect Dis 2006, 43:658-660. 10.1086/505974, 3205942, 16886163.
10. de González Requena D, Blanco F, Garcia-Benayas T, et al. Correlation between lopinavir plasma levels and lipid abnormalities in patients taking Lopinavir/ritonavir. AIDS Patient Care STDS 2003, 17:443-445. 10.1089/108729103322395465, 14588081.
11. Gutiérrez F, Padilla S, Navarro A, Masiá M, Hernández I, Ramos J, Esteban A, Martin-Hidalgo A. Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens. J Acquir Immune Defic Syndr 2003, 33:594-600. 10.1097/00126334-200308150-00007, 12902803.
12. León A, Martinez E, Sarasa M, López Y, Mallolas J, De Lazzari E, Laguno M, Milincovic A, Blanco JL, Larrousse M, Lonca M, Gatell JM. Impact of steady-state lopinavir plasma levels on plasma lipids and body composition after 24 weeks of Lopinavir containing therapy free of thymidine analogues. J Antimicrob Chemother 2007, 60:824-830. 10.1093/jac/dkm285, 17712031.
13. Ren Y, Nuttall JJ, Egbers C, Eley BS, Meyers TM, Smith PJ, Maartens G, McIlleron HM. Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr 2008, 47:566-569. 10.1097/QAI.0b013e3181642257, 18197120.
14. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2008, 31:S55-S60. American Diabetes Association.
15. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239. 10.1161/01.CIR.0000133317.49796.0E, 15249516.
16. ACTG adherence follow-up questionnaire 2006, http://www.caps.ucsf.edu/tools/surveys/pdf/2098.4188.pdf, on the 22 December 2006, ACTG adherence follow-up questionnaire.
17. Hurst M, Faulds D. Lopinavir. Drugs 2000, 60:1371-1379. 10.2165/00003495-200060060-00009, 11152017.
18. Bierman WF, van Vonderen MG, Veldkamp AI, Burger DM, Danner SA, Reiss P, van Agtmael MA. The lopinavir/ritonavir-associated rise in lipids is not related to lopinavir or ritonavir plasma concentration. Antivir Ther 2011, 16:647-655. 10.3851/IMP1824, 21817186.
19. Decloedt EH, McIlleron H, Smith P, Merry C, Orrell C, Maartens G. Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampicin with adjusted doses of lopinavir-ritonavir tablets. AAC 2011, 55:3195-3200.
20. Bazzoli C, Jullien V, Le Tiec C, Rey E, Taburet AM. Intracellular pharmacokinetics of antiretroviral drugs in HIV infected patients, and their correlation with drug action. Clin Pharmacokinet 2010, 49:17-45. 10.2165/11318110-000000000-00000, 20000887.
21. Carr A, Samaras K, Chisholm DJ, Cooper D. Pathogenesis of HIV-1-protease inhibitor associated peripheral lipodystrophy, hyperlipidaemia and insulin resistance. Lancet 1998, 351:1881-1883. 10.1016/S0140-6736(98)03391-1, 9652687.
22. Bongiovanni M, Bini T, Cicconi P, Landonio S, Meraviglia P, Testa L, Di Biagio A, Chiesa E, Tordato F, Biasi P, Adorni F, Monforte AD. Predictive factors of hyperlipidemia in HIV-infected subjects receiving lopinavir/ritonavir. AIDS Res Hum Retroviruses 2006, 22:132-138. 10.1089/aid.2006.22.132, 16478394.
23. Tarr P, Telenti A. Toxigenetics of antiretroviral therapy: genetic factors that contribute to metabolic complications. Antivir Ther 2007, 12:999-1013.
24. Rhee MS, Hellinger JA, Sheble-Hall S, Cohen CJ, Greenblatt DJ. Relationship between plasma protease inhibitor concentrations and lipid elevations in HIV patients on a double-boosted protease inhibitor regimen (saquinavir/lopinavir/ritonavir). J Clin Pharmacol 2010, 50:392-400. 10.1177/0091270009339739, 20097936.
25. Ter Hostede HJM, Koopmans PP, Burger DM, Sprenger HG, Napel CT, Vriesendorp V, Richter C. Lopinavir plasma concentrations and serum lipids in therapy naïve HIV-patients: A sub- analysis of the FREE study. Pharmacology & Pharmacy 2012, 3:90-96. 10.4236/pp.2012.31013, 23233861.